Diane C. Young - Aug 17, 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP, CHIEF MEDICAL OFFICER
Signature
/s/ Sam Martin, attorney-in-fact for Diane C. Young
Stock symbol
CLDX
Transactions as of
Aug 17, 2022
Transactions value $
-$389,545
Form type
4
Date filed
8/19/2022, 04:05 PM
Previous filing
Jun 17, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $197K +19K +898.35% $10.38 21.1K Aug 17, 2022 Direct
transaction CLDX Common Stock Sale -$709K -19K -89.98% $37.30 2.12K Aug 17, 2022 Direct F1
transaction CLDX Common Stock Options Exercise $122K +45K +2127.66% $2.71* 47.1K Aug 17, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option Options Exercise $0 -19K -28.19% $0.00 48.4K Aug 17, 2022 Common Stock 19K $10.38 Direct F2
transaction CLDX Incentive Stock Option Options Exercise $0 -45K -75% $0.00 15K Aug 17, 2022 Common Stock 45K $2.71 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.30 to $37.35 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on July 8, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.